I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives

Hypertension

Volumn 32, Issue 6, 1998, Pages 1022-1027

  Wenzel, René Roland ^b   Spieker, Lukas ^b   Qui, Su ^b   Shaw, Sidney ^b   Lüscher, Thomas Felix ^b   Noll, Georg ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

Hypertension, essential; Moxonidine; Norepinephrine; Renin; Sympathetic nervous system

Indexed keywords

IMIDAZOLINE DERIVATIVE; MOXONIDINE; NORADRENALIN; RENIN; ANTIHYPERTENSIVE AGENT; CATECHOLAMINE; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HUMAN; MALE; MUSCLE INNERVATION; NORADRENALIN BLOOD LEVEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SYMPATHETIC NERVE; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; ELECTROMYOGRAPHY; HYPERTENSION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATECHOLAMINES; DOUBLE-BLIND METHOD; ELECTROMYOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; RECEPTORS, DRUG; RENIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 0032217173     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.6.1022     Document Type: Article

References (32)

1. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1989;14:177-183.
2. Yamada Y, Miyajima E, Tochikubo O, Matsukawa T, Ishii M. Age-related changes in muscle sympathetic nerve activity in essential hypertension. Hypertension. 1989;13:870-877.
3. Wallin BG, Morlin C, Hjemdahl P. Muscle sympathetic activity and venous plasma noradrenaline concentrations during static exercise in normotensive and hypertensive subjects. Acta Physiol Scand. 1987;129:489-497.
4. Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther. 1993;264:172-182.
5. van Zwieten PA. Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine. J Hypertens. 1997; 15:117-125.
6. Macphee GJ, Howie CA, Elliott HL, Reid JL. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. Br J Clin Pharmacol. 1992;33:261-267.
7. Planitz V. Comparison of moxonidine and clonidine HCl in treating patients with hypertension. J Clin Pharmacol. 1987;27:46-51.
8. Bohmann C, Schollmeyer P, Rump LC. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn Schmiedebergs Arch Pharmacol. 1994;349:118-124.
9. Michel MC, Brodde OE, Schnepel B, Behrendt J, Tschada R, Motulsky HJ, Insel PA. [3H]Idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site. Mol Pharmacol. 1989;35: 324-330.
10. Kuppers HE, Jager BA, Luszick JH, Grave MA, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens. 1997;15:93-97.
11. Mitrovic V, Patyna W, Huting J, Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther. 1991;5:967-972.
12. Kirch W, Hutt HJ, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol. 1990;30:1088-1095.
13. Delius W, Hagbarth KE, Hongell A, Wallin BG. General characteristics of sympathetic activity in human muscle nerves. Acta Physiol Scand. 1972;84:65-81.
14. Delius W, Hagbarth KE, Hongell A, Wallin BG. Manoeuvres affecting sympathetic outflow in human muscle nerves. Acta Physiol Scand. 1972; 84:82-94.
15. Mark AL, Victor RG, Nerhed C, Wallin BG. Microneurographic studies of the mechanisms of sympathetic nerve responses to static exercise in humans. Circ Res. 1985;57:461-469.
16. Victor RG, Leimbach WJ, Seals DR, Wallin BG, Mark AL. Effects of the cold pressor test on muscle sympathetic nerve activity in humans. Hypertension. 1987;9:429-436.
17. Wallin BG. Intraneural recordings of normal and abnormal sympathetic activity in man. In: Bannister, SR, ed. Autonomic Failure. Oxford, England: Oxford University Press; 1988:177-195.
18. Wallin BG. Relationship between sympathetic nerve traffic and plasma concentrations of noradrenaline in man. Pharmacol Toxicol. 1988; 63:9-11.
19. Fagius J, Karhuvaara S. Sympathetic activity and blood pressure increases with bladder distension in humans. Hypertension. 1989;14: 511-517.
20. Trenk D, Wagner F, Jahnchen E, Planitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol. 1987;27:988-893.
21. Noll G, Wenzel RR, de Marchi S, Shaw S, Lüscher TF. Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation. 1997;95:2286-2292.
22. Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, Lüscher TF, Noll G. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol. 1997;29:1607-1614.
23. Noll G, Wenzel RR, Schneider M, Oesch V, Binggeli C, Shaw S, Weidmann P, Lüscher TF. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation. 1996;93:866-869.
24. Rudolph M, Janssen W, Strassner M. Determination of moxonidine (BDF 5895) in plasma by gas chromatography-negative ion chemical ionization mass spectrometry. J Pharm Biomed Anal. 1992;10:323-328.
25. Hjemdahl P. Catecholamine measurements by high-performance liquid chromatography. Am J Physiol. 1984;247:E13-E20.
26. Converse RJ, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad TF, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912-1918.
27. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
28. Likungu J, Molderings GJ, Gothert M. Presynaptic imidazoline receptors and alpha 2-adrenoceptors in the human heart: discrimination by clonidine and moxonidine. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:689-692.
29. Hohage H, Schlatter E, Greven J. Effects of moxonidine and clonidine on renal function and blood pressure in anesthetized rats. Clin Nephrol. 1997;47:316-324.
30. Julius S, Randall OS, Esler MD, Kashima T, Ellis C, Bennett J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res. 1975;36:199-207.
31. Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje JF Jr, Mohanty PK. Autonomie pathophysiology in heart failure patients: sympathetic-cholinergic interrelations. J Clin Invest. 1990;85:1362-1371.
32. Swedberg K. Sympathetic neurohormonal modulation in cardiovascular disease. Presented at: Heart Failure 1997 meeting; May 25, 1997; Cologne, Germany.